Search Result

Results for "

renal reabsorption

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Amino acid Transporter (1) Anion Exchangers (1) Biochemical Assay Reagents (3) Carbonic Anhydrase (1) Drug Derivative (1) Drug Metabolite (2) Endogenous Metabolite (1) Endothelin Receptor (1) Environmental Pollutants (1) Ferroptosis (1) GLUT (1) Keap1-Nrf2 (1) Na+/H+ Exchanger (NHE) (1) Natriuretic Peptide Receptor (NPR) (1) Reference Standards (4) ROS Kinase (1) SGLT (6) URAT1 (1) Vasopressin Receptor (1) Xanthine Oxidase (1)
By Research Areas:	Cancer (2) Cardiovascular Disease (5) Infection (1) Inflammation/Immunology (2) Metabolic Disease (16) Neurological Disease (1)

By Targets:

Amino acid Transporter (1)

Anion Exchangers (1)

Biochemical Assay Reagents (3)

Carbonic Anhydrase (1)

Drug Derivative (1)

Drug Metabolite (2)

Endogenous Metabolite (1)

Endothelin Receptor (1)

Environmental Pollutants (1)

Ferroptosis (1)

GLUT (1)

Keap1-Nrf2 (1)

Na+/H+ Exchanger (NHE) (1)

Natriuretic Peptide Receptor (NPR) (1)

Reference Standards (4)

ROS Kinase (1)

SGLT (6)

URAT1 (1)

Vasopressin Receptor (1)

Xanthine Oxidase (1)

By Research Areas:

Cancer (2)

Cardiovascular Disease (5)

Infection (1)

Inflammation/Immunology (2)

Metabolic Disease (16)

Neurological Disease (1)

Inhibitors & Agonists

Inhibitory Antibodies

Natural
Products

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-A0080

Aminohippurate sodium 4 Publications Verification Sodium p-aminohippurate; p-Aminohippuric acid sodium salt	Biochemical Assay Reagents
Aminohippurate sodium is a renal tubular transport inhibitor and a substrate for organic anion transporters. Aminohippurate sodium inhibits renal tubular reabsorption of phosphate and promotes increased urinary phosphate excretion. Aminohippurate sodium inhibits renal tubular reabsorption of vitamin C as well as the transport of glucose .

HY-W042301

Xipamide	Anion Exchangers Carbonic Anhydrase Endothelin Receptor	Cardiovascular Disease
Xipamide is an orally active carbonic anhydrase (CA) inhibitor and Na ⁺/Cl ^--potassium transporter inhibitor with diuretic and antihypertensive effects. Xipamide reduces NaCl reabsorption by inhibiting the Cl ^-/NaCO₃ ^- anion exchanger, and increases calcium reabsorption while promoting potassium and magnesium excretion. Xipamide is mainly cleared via the renal pathway and causes a temporary decrease in glomerular filtration rate under specific conditions. Xipamide does not affect Ca ²⁺ signaling induced by endothelin-1 and other factors, nor does it inhibit various ion cotransport or pump activities in red blood cells. Xipamide can be used in researches related to cardiovascular diseases, hypertension (especially with left ventricular hypertrophy), advanced renal failure, and liver cirrhosis with ascites .

HY-156696

S3226	Na+/H+ Exchanger (NHE)	Metabolic Disease
S3226 is a highly selective NHE-3 inhibitor (IC₅₀<1 μM) that specifically blocks NHE-3-mediated sodium transport. S3226 significantly inhibits blastocyst formation and expansion in mouse embryos, and reduces fluid and electrolyte reabsorption in rat proximal tubules in a dose-dependent manner. S3226 effectively alleviates ischemia-induced acute renal failure by improving renal function parameters, reducing renal tubular injury and restoring intracellular pH homeostasis, without interfering with the normal tubuloglomerular feedback response. S3226 is widely used in studies of acute renal failure and related pathological mechanisms .

HY-W013266

N4-Acetylsulfamethoxazole Acetylsulfamethoxazole	Drug Metabolite	Infection Metabolic Disease
N4-Acetylsulfamethoxazole (Acetylsulfamethoxazole) is the N4-acetylated metabolite of Sulfamethoxazole (HY-B0322) .

HY-N0394R

L-Cystine (Standard)	Reference Standards Endogenous Metabolite Ferroptosis ROS Kinase Keap1-Nrf2	Metabolic Disease Inflammation/Immunology Cancer
L-Cystine (Standard) is the analytical standard of L-Cystine. This product is intended for research and analytical applications. L-Cystine, the extracellular form of L-Cysteine (HY-Y0337), is a nutritionally dispensable semiessential sulfur-containing amino acid, occurring in proteins of plants and animals. L-Cystine induces Nrf2 protein elevation in a Keap1 (HY-P75897)-dependent manner and activates Nrf2 transcription factor. L-cystine can elicit cytoprotection by reducing ROS generation and protecting against oxidant- or doxorubicin-induced apoptosis. The reduced reabsorption of L-Cystine in renal tubules and its poor solubility in urine are the important causes of cystine precipitation and cystine crystal formation eventually leading to kidney stones. L-Cystine combined with L-theanine (HY-15121) enhances the production of antigen-specific IgG by increasing glutathione (GSH) levels and T helper 2 (Th2) mediated responses in mice. L-Cystine is promising for research of cystinuria and cystinosis

HY-13414

Remogliflozin Remogliflozin A	SGLT	Metabolic Disease
Remogliflozin (Remogliflozin A) is an orally active, highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor, with a K_i of 12.4 nM for human SGLT2 and 26.0 nM for rat SGLT2. Remogliflozin increases urinary glucose excretion by inhibiting renal glucose reabsorption. Without insulin stimulation, remogliflozin suppresses the elevation of plasma glucose, reduces fasting blood glucose and glycated hemoglobin, and improves glycosuria, hyperglycemia, hyperinsulinemia, hypertriglyceridemia and insulin resistance in diabetic rodents. Remogliflozin can be used in research related to type 2 diabetes .

HY-109542

Cyclopenthiazide	Biochemical Assay Reagents	Metabolic Disease
Cyclopenthiazide is a benzothiadiazine diuretic with antihypertensive properties. Cyclopenthiazide exerts a diuretic effect by inhibiting the reabsorption of sodium chloride and water at the distal renal tubules. Cyclopenthiazide increases the excretory capacity of the rat kidney .

HY-109018B

Velagliflozin proline hydrate 1 Publications Verification	SGLT	Metabolic Disease
Velagliflozin proline hydrate is the clinical form of Velagliflozin (HY-109018). Velagliflozin is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .

HY-179107

SLC6A19-IN-3	Amino acid Transporter	Metabolic Disease
SLC6A19-IN-3 (Compound 83-P1-P2) is a potent, selective and orally active SLC6A19 inhibitor with an IC₅₀ of 28 nM. SLC6A19-IN-3 can block SLC6A19-mediated transmembrane transport of phenylalanine, reducing intestinal absorption of phenylalanine from food and renal tubular reabsorption of phenylalanine. SLC6A19-IN-3 can be used for the research of metabolic disease, such as phenylketonuria .

HY-106300

AA 193	Xanthine Oxidase	Cardiovascular Disease Metabolic Disease
AA 193 is an orally active uricosuric agent. AA 193 inhibits the net reabsorption of uric acid in nephrons, regulates the renal reabsorption process of filtered uric acid, promotes uric acid excretion in a dose-dependent manner, and reduces serum uric acid levels. AA 193 mildly inhibits the activity of xanthine dehydrogenase (XDH). AA 193 can be used in studies related to hyperuricemia .

HY-120147

Ethiazide	Natriuretic Peptide Receptor (NPR)	Cardiovascular Disease
Ethiazide is a thiazole diuretic which inhibits renal reabsorption of sodium and water, thereby increasing urine excretion, reducing fluid retention, and lowering blood volume and blood pressure. Ethiazide can be used for cardiovascular research .

HY-109018A

Velagliflozin proline 1 Publications Verification	SGLT	Metabolic Disease
Velagliflozin proline is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin proline reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .

HY-109542R

Cyclopenthiazide (Standard)	Biochemical Assay Reagents Reference Standards	Metabolic Disease
Cyclopenthiazide (Standard) is the analytical standard of Cyclopenthiazide. This product is intended for research and analytical applications. Cyclopenthiazide is a benzothiadiazine diuretic with antihypertensive properties. Cyclopenthiazide exerts a diuretic effect by inhibiting the reabsorption of sodium chloride and water at the distal renal tubules. Cyclopenthiazide increases the excretory capacity of the rat kidney .

HY-165423

DM-4111	Vasopressin Receptor Drug Metabolite	Cardiovascular Disease
DM-4111, one of the major monohydroxyl metabolites of Tolvaptan (HY-17000), is a potent vasopressin V₂ receptor inhibitor. DM-4111 inhibits water reabsorption in the renal tubules, thereby promoting the excretion of electrolyte-free water. DM-4111 is promising for research of cardiovascular diseases .

HY-183658

URAT1/GLUT9-IN-3	URAT1 GLUT	Metabolic Disease Inflammation/Immunology
URAT1/GLUT9-IN-3 is an orally active URAT1/GLUT9 dual inhibitor with IC₅₀ values of 4.01 and 1.60 μM. URAT1/GLUT9-IN-3 inhibits URAT1-mediated uric acid uptake and GLUT9-mediated uric acid transport, reducing renal urate reabsorption. URAT1/GLUT9-IN-3 reduces serum uric acid levels in hyperuricemic mice. URAT1/GLUT9-IN-3 can be used for the researches of gout and hyperuricemia .

HY-Y0282

Sodium bromide NSC 77384; Sanibrom 40	Environmental Pollutants	Neurological Disease
Sodium bromide (NSC 77384; Sanibrom 40) is a GABA-ergic system modulator that crosses the blood-brain barrier, and it effectively reduces and blocks epileptiform discharges. Sodium bromide exerts significant anticonvulsant effects by enhancing GABA-ergic inhibitory functions, such as increasing the amplitude of inhibitory postsynaptic currents and paired-pulse inhibition. Sodium bromide specifically enhances stimulation-induced extracellular alkalosis without affecting baseline pH or subsequent acidosis processes. Sodium bromide exhibits species-specific pharmacokinetic characteristics, competes with chloride ions for renal tubular reabsorption sites, and serves as a marker for extracellular fluid volume. Sodium bromide can be used in the research of epilepsy and related neurological diseases .

HY-109018AR

Velagliflozin proline (Standard)	Reference Standards SGLT	Metabolic Disease
Velagliflozin proline (Standard) is the analytical standard of Velagliflozin (proline) (HY-109018A). This product is intended for research and analytical applications. Velagliflozin proline is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin proline reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .

HY-109018BR

Velagliflozin proline hydrate (Standard)	Reference Standards SGLT	Metabolic Disease
Velagliflozin proline hydrate (Standard) is the analytical standard of Velagliflozin (proline hydrate) (HY-109018B). This product is intended for research and analytical applications. Velagliflozin proline hydrate is the clinical form of Velagliflozin (HY-109018). Velagliflozin is an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor with antidiabetic activity. Velagliflozin reduces renal glucose reabsorption and stimulates glycosuria, which lowers blood sugar and insulin concentrations .

HY-178734

Janagliflozin	SGLT	Metabolic Disease
Janagliflozin is orally active and highly selective sodium-glucose cotransporter 2 (SGLT2) inhibitor (IC₅₀=0.0058 μM for SGLT2 and 4.802 μM for SGLT1). Janagliflozin inhibits SGLT2 in the proximal renal tubules, reducing glucose reabsorption and promoting urinary glucose excretion (UGE) to lower blood glucose levels. Janagliflozin is promising for research of type 2 diabetes mellitus .

HY-W343043

Pyrazinoylguanidine PZG	Drug Derivative	Cardiovascular Disease Metabolic Disease
Pyrazinoylguanidine (PZG) is an analogue of the potassium sparing diuretic, Amiloride (HY-B0285). Pyrazinoylguanidine can lower the systolic and diastolic blood pressure of patients with primary hypertension, has a certain effect on reducing heart rate, and does not affect the concentrations of electrolytes such as sodium, potassium, and chloride in the blood serum. Pyrazinoylguanidine can reduce the hyperglycemia and hyperinsulinemia in type 2 diabetes, reduce the levels of triglycerides, cholesterol, and free fatty acids, and reverse the hyperglycemia and hyperlipidemia induced by thiazide diuretics, such as Hydrochlorothiazide (HY-B0252). Pyrazinoylguanidine ican nhibit the reabsorption of urea by the renal tubules, thereby increasing the clearance rate and excretion volume of urea, reducing the serum urea concentration, and minimizing its toxic accumulation .

Cat. No.	Product Name	Target	Research Area	Image

HY-P9939

Burosumab 1 Publications Verification KRN23; N5KG1_C10_LH; UX-023	Inhibitory Antibodies	Metabolic Disease Cancer
Burosumab (KRN23) is a humanized FGF23-neutralizing antibody. By neutralizing FGF23, Burosumab blocks its inhibitory effect on renal phosphate reabsorption, thereby increasing serum phosphate levels and improving abnormal bone mineralization. Burosumab can be used in the research of diseases such as X-linked hypophosphatemia (XLH) and osteomalacia .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-N0394R

L-Cystine (Standard)	Structural Classification Human Gut Microbiota Metabolites Microorganisms Amino acids Endogenous metabolite Source Classification	Reference Standards Endogenous Metabolite Ferroptosis ROS Kinase Keap1-Nrf2
L-Cystine (Standard) is the analytical standard of L-Cystine. This product is intended for research and analytical applications. L-Cystine, the extracellular form of L-Cysteine (HY-Y0337), is a nutritionally dispensable semiessential sulfur-containing amino acid, occurring in proteins of plants and animals. L-Cystine induces Nrf2 protein elevation in a Keap1 (HY-P75897)-dependent manner and activates Nrf2 transcription factor. L-cystine can elicit cytoprotection by reducing ROS generation and protecting against oxidant- or doxorubicin-induced apoptosis. The reduced reabsorption of L-Cystine in renal tubules and its poor solubility in urine are the important causes of cystine precipitation and cystine crystal formation eventually leading to kidney stones. L-Cystine combined with L-theanine (HY-15121) enhances the production of antigen-specific IgG by increasing glutathione (GSH) levels and T helper 2 (Th2) mediated responses in mice. L-Cystine is promising for research of cystinuria and cystinosis

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks